摘要
减毒Edmonston谱系麻疹病毒(MV-Edm)疫苗株可以优先感染和裂解各种各样的癌细胞。 溶瘤MV-Edm衍生物被遗传工程化以表达人癌胚抗原(MV-CEA病毒)或人钠碘转运体(MV-NIS病毒),并且目前正在临床试验中针对卵巢癌,多形性成胶质细胞瘤,多发性骨髓瘤, 间皮瘤,头颈癌,乳腺癌和恶性周围神经鞘瘤。 本综述介绍了促进MV-Edm菌株临床翻译的基础和临床前数据,总结了迄今为止这一溶瘤平台的临床结果。 此外,我们讨论最新的临床相关MV-Edm载体的发展和创造性的战略,为未来的翻译步骤。
关键词: 癌症基因治疗,麻疹病毒临床试验,MV-CEA,MV-NIS,溶瘤麻疹,病毒疗法。
图形摘要
Current Cancer Drug Targets
Title:Clinical Trials with Oncolytic Measles Virus: Current Status and Future Prospects
Volume: 18 Issue: 2
关键词: 癌症基因治疗,麻疹病毒临床试验,MV-CEA,MV-NIS,溶瘤麻疹,病毒疗法。
摘要: Attenuated Edmonston lineage measles virus (MV-Edm) vaccine strains can preferentially infect and lyse a wide variety of cancer cells. Oncolytic MV-Edm derivatives are genetically engineered to express the human carcinoembryonic antigen (MV-CEA virus) or the human sodium iodide symporter (MV-NIS virus) and are currently being tested in clinical trials against ovarian cancer, glioblastoma multiforme, multiple myeloma, mesothelioma, head and neck cancer, breast cancer and malignant peripheral nerve sheath tumors. This review describes the basic and preclinical data that facilitated the clinical translation of MV-Edm strains, and summarizes the clinical results of this oncolytic platform to date. Furthermore, we discuss the latest clinically relevant MV-Edm vector developments and creative strategies for future translational steps.
Export Options
About this article
Cite this article as:
Clinical Trials with Oncolytic Measles Virus: Current Status and Future Prospects, Current Cancer Drug Targets 2018; 18 (2) . https://dx.doi.org/10.2174/1568009617666170222125035
DOI https://dx.doi.org/10.2174/1568009617666170222125035 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Chemotherapeutic Targeting of Cell Death Pathways
Anti-Cancer Agents in Medicinal Chemistry Midkine: A Promising Molecule for Drug Development to Treat Diseases of the Central Nervous System
Current Pharmaceutical Design Environmental Factors and Hypertension
Current Pharmaceutical Design Chylothorax
Current Respiratory Medicine Reviews Development of Lymphatic Vessels: Tumour Lymphangiogenesis and Lymphatic Invasion
Current Medicinal Chemistry Small Molecular Inhibitors Targeting Chromatin Regulating Proteins for Cancer
Current Protein & Peptide Science Ligand-Based Drug Design of Novel MARK-3 Inhibitors in Cancer
Current Bioactive Compounds Targeting Indoleamine 2,3-dioxygenase (IDO) to Counteract Tumour- Induced ImmuneDysfunction: From Biochemistry to Clinical Development
Endocrine, Metabolic & Immune Disorders - Drug Targets 5-Fluorouracil Buccal Tablets for Locoregional Chemotherapy of Oral Squamous Cell Carcinoma: Formulation, Drug Release and Histological Effects on Reconstituted Human Oral Epithelium and Porcine Buccal Mucosa
Current Drug Delivery Histone Deacetylase Inhibitors: A New Wave of Molecular Targeted Anticancer Agents
Recent Patents on Anti-Cancer Drug Discovery The Role of BMPs in Bone Anabolism and their Potential Targets SOST and DKK1
Current Molecular Pharmacology A Review of Fish Lectins
Current Protein & Peptide Science Natural Polyphenols and their Synthetic Analogs as Emerging Anticancer Agents
Current Drug Targets Modulators of Inhibitor of Growth (ING) Family Expression in Development and Disease
Current Drug Targets Notch Signaling Proteins: Legitimate Targets for Cancer Therapy
Current Protein & Peptide Science Clinical Applications of Pinhole Single Photon Emission Tomography
Current Medical Imaging Image-Guided Drug Delivery with Single-Photon Emission Computed Tomography: A Review of Literature
Current Drug Targets Receptor Tyrosine Kinases are Signaling Intermediates of G Protein- Coupled Receptors
Current Pharmaceutical Design Bortezomib Enhances the Antitumor Effects of Interferon-β Gene Transfer on Melanoma Cells
Anti-Cancer Agents in Medicinal Chemistry Perspectives for Novel Mixed Diruthenium-Organic Drugs as Metallopharmaceuticals in Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry